Nuochengjianhua (688428.SH) disclosed its 2023 annual report. The company achieved operating income of 7 during the reporting period...
According to the Zhitong Finance App, Nuocheng Jianhua (688428.SH) disclosed its 2023 annual report. The company achieved operating revenue of 739 million yuan (RMB, same below) during the reporting period, an increase of 18.09% over the previous year. Net loss attributable to shareholders of listed companies was 631 million yuan, and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 626 million yuan. Losses narrowed year-on-year.
During the reporting period, the company's revenue increased by 18.09% over the same period last year, mainly due to continued growth in obutinib sales. In 2023, the company's core product obutinib (INOC)) Sales were $671 million, up 18.52% year-on-year from 2022. Furthermore, the narrowing of losses was mainly due to increased operating income and interest income, reduced sales expenses, and reduced exchange losses, which offset the increase in R&D expenses.